Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.04 (overall 0.02) | 0.04 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: zolimomab aritox, mt-3724, citatuzumab bogatox +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 353 | 0.91 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7458
Sealed predictions
- RPL5 in dopamine neurons, braak-0.21 (p 0.586) → +0.53 (p 0.145)receipt 7466
Swarm cases
receipt 7466: RPL5 in dopamine neurons, braak
- power
- full sample +0.13 (p 0.603, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.646, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.526, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.30, sign flips 0; without severely affected donors +0.13 (p 0.603, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts